Anaphylaxis is an inappropriate reaction of the immune system to normal harmless substances. It generally has a rapid onset, strong reaction, and rapid subsidence. It has obvious genetic tendencies and individual differences. Currently, the prevalence of allergic diseases is increasing rapidly worldwide, affecting approximately 25% of the global population.
Abnormalities in type 2 immune pathways are important factors in inducing allergic diseases. Type 2 immune pathway refers to an inflammatory pathway in which Th2 cells (T helper 2) play a key role, and various cytokines such as IL-4, IL-5, IL-13, and TSLP are involved.
Depending on where the inflammatory reaction occurs, abnormal type 2 immune pathways can induce different allergic diseases, such as skin (atopic dermatitis, chronic spontaneous urticaria, etc.), respiratory tract (chronic sinusitis, asthma, chronic obstruction, etc.) lung disease, etc.), digestive tract (eosinophilic esophagitis), cardiovascular (eosinophilic granulomatous vasculitis), etc.
Biological targeted drugs mainly reduce the inflammatory response and activity of immune cells by binding to targets such as specific regulatory factors in the type 2 immune pathway; Small molecule targeted drugs include JAK inhibitors and TYK2 inhibitors, which exert immunomodulatory effects by blocking the JAK/STAT pathway. Compared with traditional anti-allergic drugs, targeted drugs have better efficacy in severe or drug-resistant patients, and the drugs themselves are safer, and have gradually become the mainstream trend in the development of anti-allergic drugs.
The global Type 2 Inflammation Targeting Drugs market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
Publisher' newest research report, the 鈥淭ype 2 Inflammation Targeting Drugs Industry Forecast鈥� looks at past sales and reviews total world Type 2 Inflammation Targeting Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Type 2 Inflammation Targeting Drugs sales for 2024 through 2030. With Type 2 Inflammation Targeting Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Type 2 Inflammation Targeting Drugs industry.
This Insight Report provides a comprehensive analysis of the global Type 2 Inflammation Targeting Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Type 2 Inflammation Targeting Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Type 2 Inflammation Targeting Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Type 2 Inflammation Targeting Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Type 2 Inflammation Targeting Drugs.
United States market for Type 2 Inflammation Targeting Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Type 2 Inflammation Targeting Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Type 2 Inflammation Targeting Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Type 2 Inflammation Targeting Drugs players cover Sanofi, Novartis, GSK, Amgen and AstraZeneca, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Type 2 Inflammation Targeting Drugs market by product type, application, key players and key regions and countries.
Segmentation by type
IL-4R
TSLP
IL-5
JAK
IgE
IL-13
IL-33
Others
Segmentation by application
Atopic Dermatitis
Asthma
Chronic Sinusitis with Nasal Polyps
Chronic Obstructive Pulmonary Disease
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Novartis
GSK
Amgen
AstraZeneca
Pfizer
Teva
Otsuka Pharmaceutical
Roche
AbbVie
Leo Pharma
Eli Lilly and Company
Keymed Biosciences
Mabpharm
Genrix Bio
Dragon Boat Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Sunshine Guojian
Qyuns Therapeutics
Biosion
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Type 2 Inflammation Targeting Drugs Market Size 2019-2030
2.1.2 Type 2 Inflammation Targeting Drugs Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Type 2 Inflammation Targeting Drugs Segment by Type
2.2.1 IL-4R
2.2.2 TSLP
2.2.3 IL-5
2.2.4 JAK
2.2.5 IgE
2.2.6 IL-13
2.2.7 IL-33
2.2.8 Others
2.3 Type 2 Inflammation Targeting Drugs Market Size by Type
2.3.1 Type 2 Inflammation Targeting Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Type 2 Inflammation Targeting Drugs Market Size Market Share by Type (2019-2024)
2.4 Type 2 Inflammation Targeting Drugs Segment by Application
2.4.1 Atopic Dermatitis
2.4.2 Asthma
2.4.3 Chronic Sinusitis with Nasal Polyps
2.4.4 Chronic Obstructive Pulmonary Disease
2.4.5 Others
2.5 Type 2 Inflammation Targeting Drugs Market Size by Application
2.5.1 Type 2 Inflammation Targeting Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Type 2 Inflammation Targeting Drugs Market Size Market Share by Application (2019-2024)
3 Type 2 Inflammation Targeting Drugs Market Size by Player
3.1 Type 2 Inflammation Targeting Drugs Market Size Market Share by Players
3.1.1 Global Type 2 Inflammation Targeting Drugs Revenue by Players (2019-2024)
3.1.2 Global Type 2 Inflammation Targeting Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Type 2 Inflammation Targeting Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Type 2 Inflammation Targeting Drugs by Regions
4.1 Type 2 Inflammation Targeting Drugs Market Size by Regions (2019-2024)
4.2 Americas Type 2 Inflammation Targeting Drugs Market Size Growth (2019-2024)
4.3 APAC Type 2 Inflammation Targeting Drugs Market Size Growth (2019-2024)
4.4 Europe Type 2 Inflammation Targeting Drugs Market Size Growth (2019-2024)
4.5 Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size Growth (2019-2024)
5 Americas
5.1 Americas Type 2 Inflammation Targeting Drugs Market Size by Country (2019-2024)
5.2 Americas Type 2 Inflammation Targeting Drugs Market Size by Type (2019-2024)
5.3 Americas Type 2 Inflammation Targeting Drugs Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Type 2 Inflammation Targeting Drugs Market Size by Region (2019-2024)
6.2 APAC Type 2 Inflammation Targeting Drugs Market Size by Type (2019-2024)
6.3 APAC Type 2 Inflammation Targeting Drugs Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Type 2 Inflammation Targeting Drugs by Country (2019-2024)
7.2 Europe Type 2 Inflammation Targeting Drugs Market Size by Type (2019-2024)
7.3 Europe Type 2 Inflammation Targeting Drugs Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Type 2 Inflammation Targeting Drugs by Region (2019-2024)
8.2 Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size by Type (2019-2024)
8.3 Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Type 2 Inflammation Targeting Drugs Market Forecast
10.1 Global Type 2 Inflammation Targeting Drugs Forecast by Regions (2025-2030)
10.1.1 Global Type 2 Inflammation Targeting Drugs Forecast by Regions (2025-2030)
10.1.2 Americas Type 2 Inflammation Targeting Drugs Forecast
10.1.3 APAC Type 2 Inflammation Targeting Drugs Forecast
10.1.4 Europe Type 2 Inflammation Targeting Drugs Forecast
10.1.5 Middle East & Africa Type 2 Inflammation Targeting Drugs Forecast
10.2 Americas Type 2 Inflammation Targeting Drugs Forecast by Country (2025-2030)
10.2.1 United States Type 2 Inflammation Targeting Drugs Market Forecast
10.2.2 Canada Type 2 Inflammation Targeting Drugs Market Forecast
10.2.3 Mexico Type 2 Inflammation Targeting Drugs Market Forecast
10.2.4 Brazil Type 2 Inflammation Targeting Drugs Market Forecast
10.3 APAC Type 2 Inflammation Targeting Drugs Forecast by Region (2025-2030)
10.3.1 China Type 2 Inflammation Targeting Drugs Market Forecast
10.3.2 Japan Type 2 Inflammation Targeting Drugs Market Forecast
10.3.3 Korea Type 2 Inflammation Targeting Drugs Market Forecast
10.3.4 Southeast Asia Type 2 Inflammation Targeting Drugs Market Forecast
10.3.5 India Type 2 Inflammation Targeting Drugs Market Forecast
10.3.6 Australia Type 2 Inflammation Targeting Drugs Market Forecast
10.4 Europe Type 2 Inflammation Targeting Drugs Forecast by Country (2025-2030)
10.4.1 Germany Type 2 Inflammation Targeting Drugs Market Forecast
10.4.2 France Type 2 Inflammation Targeting Drugs Market Forecast
10.4.3 UK Type 2 Inflammation Targeting Drugs Market Forecast
10.4.4 Italy Type 2 Inflammation Targeting Drugs Market Forecast
10.4.5 Russia Type 2 Inflammation Targeting Drugs Market Forecast
10.5 Middle East & Africa Type 2 Inflammation Targeting Drugs Forecast by Region (2025-2030)
10.5.1 Egypt Type 2 Inflammation Targeting Drugs Market Forecast
10.5.2 South Africa Type 2 Inflammation Targeting Drugs Market Forecast
10.5.3 Israel Type 2 Inflammation Targeting Drugs Market Forecast
10.5.4 Turkey Type 2 Inflammation Targeting Drugs Market Forecast
10.5.5 GCC Countries Type 2 Inflammation Targeting Drugs Market Forecast
10.6 Global Type 2 Inflammation Targeting Drugs Forecast by Type (2025-2030)
10.7 Global Type 2 Inflammation Targeting Drugs Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Sanofi
11.1.1 Sanofi Company Information
11.1.2 Sanofi Type 2 Inflammation Targeting Drugs Product Offered
11.1.3 Sanofi Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Sanofi Main Business Overview
11.1.5 Sanofi Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Type 2 Inflammation Targeting Drugs Product Offered
11.2.3 Novartis Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 GSK
11.3.1 GSK Company Information
11.3.2 GSK Type 2 Inflammation Targeting Drugs Product Offered
11.3.3 GSK Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 GSK Main Business Overview
11.3.5 GSK Latest Developments
11.4 Amgen
11.4.1 Amgen Company Information
11.4.2 Amgen Type 2 Inflammation Targeting Drugs Product Offered
11.4.3 Amgen Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Amgen Main Business Overview
11.4.5 Amgen Latest Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information
11.5.2 AstraZeneca Type 2 Inflammation Targeting Drugs Product Offered
11.5.3 AstraZeneca Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 AstraZeneca Main Business Overview
11.5.5 AstraZeneca Latest Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Type 2 Inflammation Targeting Drugs Product Offered
11.6.3 Pfizer Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Pfizer Main Business Overview
11.6.5 Pfizer Latest Developments
11.7 Teva
11.7.1 Teva Company Information
11.7.2 Teva Type 2 Inflammation Targeting Drugs Product Offered
11.7.3 Teva Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Teva Main Business Overview
11.7.5 Teva Latest Developments
11.8 Otsuka Pharmaceutical
11.8.1 Otsuka Pharmaceutical Company Information
11.8.2 Otsuka Pharmaceutical Type 2 Inflammation Targeting Drugs Product Offered
11.8.3 Otsuka Pharmaceutical Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Otsuka Pharmaceutical Main Business Overview
11.8.5 Otsuka Pharmaceutical Latest Developments
11.9 Roche
11.9.1 Roche Company Information
11.9.2 Roche Type 2 Inflammation Targeting Drugs Product Offered
11.9.3 Roche Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Roche Main Business Overview
11.9.5 Roche Latest Developments
11.10 AbbVie
11.10.1 AbbVie Company Information
11.10.2 AbbVie Type 2 Inflammation Targeting Drugs Product Offered
11.10.3 AbbVie Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 AbbVie Main Business Overview
11.10.5 AbbVie Latest Developments
11.11 Leo Pharma
11.11.1 Leo Pharma Company Information
11.11.2 Leo Pharma Type 2 Inflammation Targeting Drugs Product Offered
11.11.3 Leo Pharma Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Leo Pharma Main Business Overview
11.11.5 Leo Pharma Latest Developments
11.12 Eli Lilly and Company
11.12.1 Eli Lilly and Company Company Information
11.12.2 Eli Lilly and Company Type 2 Inflammation Targeting Drugs Product Offered
11.12.3 Eli Lilly and Company Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Eli Lilly and Company Main Business Overview
11.12.5 Eli Lilly and Company Latest Developments
11.13 Keymed Biosciences
11.13.1 Keymed Biosciences Company Information
11.13.2 Keymed Biosciences Type 2 Inflammation Targeting Drugs Product Offered
11.13.3 Keymed Biosciences Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Keymed Biosciences Main Business Overview
11.13.5 Keymed Biosciences Latest Developments
11.14 Mabpharm
11.14.1 Mabpharm Company Information
11.14.2 Mabpharm Type 2 Inflammation Targeting Drugs Product Offered
11.14.3 Mabpharm Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Mabpharm Main Business Overview
11.14.5 Mabpharm Latest Developments
11.15 Genrix Bio
11.15.1 Genrix Bio Company Information
11.15.2 Genrix Bio Type 2 Inflammation Targeting Drugs Product Offered
11.15.3 Genrix Bio Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Genrix Bio Main Business Overview
11.15.5 Genrix Bio Latest Developments
11.16 Dragon Boat Pharmaceutical
11.16.1 Dragon Boat Pharmaceutical Company Information
11.16.2 Dragon Boat Pharmaceutical Type 2 Inflammation Targeting Drugs Product Offered
11.16.3 Dragon Boat Pharmaceutical Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Dragon Boat Pharmaceutical Main Business Overview
11.16.5 Dragon Boat Pharmaceutical Latest Developments
11.17 Jiangsu Hengrui Pharmaceuticals
11.17.1 Jiangsu Hengrui Pharmaceuticals Company Information
11.17.2 Jiangsu Hengrui Pharmaceuticals Type 2 Inflammation Targeting Drugs Product Offered
11.17.3 Jiangsu Hengrui Pharmaceuticals Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
11.17.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
11.18 Sunshine Guojian
11.18.1 Sunshine Guojian Company Information
11.18.2 Sunshine Guojian Type 2 Inflammation Targeting Drugs Product Offered
11.18.3 Sunshine Guojian Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Sunshine Guojian Main Business Overview
11.18.5 Sunshine Guojian Latest Developments
11.19 Qyuns Therapeutics
11.19.1 Qyuns Therapeutics Company Information
11.19.2 Qyuns Therapeutics Type 2 Inflammation Targeting Drugs Product Offered
11.19.3 Qyuns Therapeutics Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Qyuns Therapeutics Main Business Overview
11.19.5 Qyuns Therapeutics Latest Developments
11.20 Biosion
11.20.1 Biosion Company Information
11.20.2 Biosion Type 2 Inflammation Targeting Drugs Product Offered
11.20.3 Biosion Type 2 Inflammation Targeting Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 Biosion Main Business Overview
11.20.5 Biosion Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
